Circadian Board changes and renewal

Company News

Circadian Technologies (ASX:CIR) has announced several changes to its board of directors at its Annual General Meeting.

Circadian Technologies’ Chair, Ms Dominique Fisher, did not seek re-election as a director at the AGM following 10 years of service to the company.

"Her tenure spanned Circadian’s transition from a biotechnology ‘incubator’ to a developer of biologic therapies targeting members of the VEGF pathway for the treatment of cancer and eye diseases," said the company in a statement. "The company thanks Ms Fisher for her contributions to Circadian and wishes her well with her future endeavours."

The Company said it had also accepted the resignations of non-executive directors Ms Tina McMeckan and Dr Russell Howard. Ms McMeckan and Dr Howard have served as directors of the Company for eight and three years respectively. 

"Circadian thanks the retiring directors for their dedicated and professional service and we wish them every success in their future ventures," it said, going on to announce the appointments of Mr Geoffrey Kempler and Mr Michael Sistenich to its Board of Directors.

Mr Kempler has been appointed Circadian’s Chairman.  

According to the Company, Mr Kempler has extensive experience in investment and business development and the biotechnology industry. He is currently CEO and Executive Chairman of Prana Biotechnology and has held operational roles as well as being responsible for the implementation of Prana’s strategic plan and commercialisation of its technology. 

"Mr Kempler’s experience as Chairman of a dual-ASX-NASDAQ listed biotechnology company, as well as his U.S. capital market and industry connections will be particularly beneficial to Circadian as it advances OPT-302 through clinical development," it said.

Mr Sistenich has over 18 years of experience as a healthcare specialist in international investment management and investment banking. He is currently Head of Corporate Development at Nohla Therapeutics, a Seattle-based biotechnology company and his previous roles include Director of Corporate Finance at Bell Potter Securities and Director of International Equities and Head of Global Healthcare Investments at Deutsche Bank.

“I am delighted to welcome both Geoffrey and Michael to Circadian’s board of directors," said Circadian CEO and Managing Director, Dr Megan Baldwin. "Their breadth of skills, experience and industry knowledge will position the company well to execute on its strategy of becoming a leading biotechnology company in the ophthalmology space.”